Clinical Efficacy of Long-Term Treatment with Amiodarone for Life-Threatening Arrhythmias

1992 ◽  
Vol 20 (Supplement) ◽  
pp. 59-62 ◽  
Author(s):  
Dieter Burckhardt
Keyword(s):  
Clinical Efficacy ◽  
Term Treatment ◽  
Long Term Treatment ◽  
Life Threatening

Clinical Efficacy of Dhatryadi Ghanavati in Shvitra (Vitiligo)

2017 ◽  
Vol 1 (4) ◽  
Author(s):  
Manjiri Walinjkar ◽  
P.D. Londhe ◽  
S. R. Makhare ◽  
Anil Avhad
Keyword(s):  
Clinical Efficacy ◽  
Skin Disorder ◽  
Total Population ◽  
Social Stigma ◽  
Term Treatment ◽  
Effective Therapy ◽  
Long Term Treatment ◽  
Percentage Area ◽  
Effective Remedy

Background: Shvitra (vitiligo) is a kind of skin disorder comprising of white coloured skin patches which is considered as a social stigma. Worldwide prevalence of Vitiligo is observed as 1% of the total population. Due to the chronic nature, long term treatment, lack of uniform effective therapy and unpredictable course the disease is usually very demoralizing for patients. Aim: To study the efficacy of ‘Dhatryadi Ghanavati’ in the management of Shvitra. Materials and Methods: Total 50 patients of Shvitra from OPD and IPD unit of Dr. M.N. Agashe Hospital, Satara were selected and provided with Dhatryadi Ghanavati 1gm B.D. for the duration of 3 months. Results: 100% relief was observed in Daha and Kandu followed by 83.33% relief was observed in Rukshata. 34.51% improvement was seen in number of patches, 34.82% in size of patches and 34.29% in percentage area involved. Color of the patches was improved by 69.01% whereas 44% improvement was seen in hair discoloration. Conclusion: The compound formulation ‘Dhatryadi Ghanavati’ was found as an effective remedy for ‘Shvitra’. The parameters like number of patches, size of patches, percentage area involved and colour of patches showed statistically highly significant results.

scholarly journals 1228 Cardiac Safety and Clinical Efficacy of High Dose Domperidone for Long-Term Treatment of Gastroparesis

2019 ◽  
Vol 114 (1) ◽  
pp. S685-S685
Author(s):  
Kevin Woods ◽  
Irene Sarosiek ◽  
Karina Espino ◽  
Marisol Ramirez ◽  
Tariq Siddiqui ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Term Treatment ◽  
High Dose ◽  
Cardiac Safety ◽  
Long Term Treatment

scholarly journals Methotrexate induced ventricular arrhythmia as a medication error: a case report

2019 ◽  
Vol 8 (9) ◽  
pp. 2163
Author(s):  
Shailja S. Shah ◽  
Sapna Gupta ◽  
Jasvin Vala ◽  
Supriya D. Malhotra ◽  
Pankaj Patel
Keyword(s):  
Ventricular Arrhythmia ◽  
Therapeutic Index ◽  
Term Treatment ◽  
Weekly Dose ◽  
Narrow Therapeutic Index ◽  
Patient Comprehension ◽  
Long Term Treatment ◽  
Daily Dose ◽  
Life Threatening

Methotrexate (MTX) is the most widely used drug in clinical practice for long term treatment of connective tissue disorders. As this drug has narrow therapeutic index, if it goes unmonitored can lead to life threatening complications. Herein we are describing the case of a patient who presented with ventricular arrhythmia, due to failure to execute MTX therapy in the prescribed frequency and took daily dose of MTX which was meant to be taken as a weekly dose pointing to failure of patient education or patient comprehension regarding MTX and finally succumbed due to cardiogenic shock. We concluded this causality as probable/likely category according to WHO-UMC causality categories. 

Long-term salvage therapy with cyclosporin A in refractory idiopathic thrombocytopenic purpura

Blood ◽  
2002 ◽  
Vol 99 (4) ◽  
pp. 1482-1485 ◽  
Author(s):  
Giovanni Emilia ◽  
Monica Morselli ◽  
Mario Luppi ◽  
Giuseppe Longo ◽  
Roberto Marasca ◽  
...  
Keyword(s):  
Cyclosporin A ◽  
Idiopathic Thrombocytopenic Purpura ◽  
Complete Response ◽  
Term Treatment ◽  
Thrombocytopenic Purpura ◽  
Long Term Treatment ◽  
Life Threatening ◽  
Difficult Challenge

Treatment of severe, chronic idiopathic thrombocytopenic purpura (ITP) refractory to most usual therapies is a difficult challenge. Little information exists on the clinical use of cyclosporin A (CyA) in the treatment of ITP. This report describes long-term treatment with CyA (median, 40 months) and follow-up (median, 36.8 months) in 12 adult patients with resistant ITP. CyA used in relatively low doses (2.5-3 mg/kg of body weight per day) led to a clinical improvement in 10 patients (83.3%). Five had a complete response (41.1%), 4 a complete response to maintenance therapy (33.3%), and one a partial response (8.3%). Two patients had no response. Most patients with a response (60%) had a long-term remission (mean, 28.6 months) after discontinuation of CyA. One patient had a relapse of ITP 4 years after CyA therapy was stopped. Side effects were moderate and transient, even in patients dependent on continued CyA treatment. CyA seems to represent reasonable salvage treatment in severe, potentially life-threatening, refractory ITP.

Sign in / Sign up

Export Citation Format

Share Document